New drug treatment for Alzheimer's disease: lessons for healthcare policy.
Melzer
D
D
Department of Community Medicine, University of Cambridge. dm214@medschl.cam.ac.uk
D000329:Advertising; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003657:Decision Making; D000077265:Donepezil; D017277:Drug Approval; D004345:Drug Industry; D035081:Editorial Policies; D019317:Evidence-Based Medicine; D033161:Government Regulation; D006291:Health Policy; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D033181:Information Dissemination; D010880:Piperidines / Q000627:therapeutic use*; D018570:Risk Assessment; D036302:Therapeutic Human Experimentation; D006113:United Kingdom; D014481:United States
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil